
    
      This trial will answer the question whether immuno-suppression improves hematopoesis and
      reduces transfusion requirements analogous to patients with aplastic anemia as the short-term
      outcome, and whether immuno-suppression accelerates leukemic transformation and influences
      survival as the long-term outcome.

      Primary endpoint: best response (CR + PR) rate at month 6
    
  